Re Appointment of Mr. Pavan Sathvik Gilaka (DIN: 09733182) as An Whole time Director of the company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals' Board has approved the re-appointment of Mr. Pavan Sathvik Gilaka (DIN: 09733182) as a Whole-time Director for a second term of 3 years, effective from October 19, 2025 to October 18, 2028, subject to shareholder approval. Mr. Gilaka holds a BBA degree and has experience in HR, Marketing, and Administration. He currently holds 77,568,000 equity shares in the company. The re-appointment was based on the recommendation of the Nomination and Remuneration Committee. The company confirmed he is not debarred from holding directorship by SEBI or any other authority, and is not related to any existing Director, KMP, or Promoter.
This is a routine re-appointment with no change in leadership. Mr. Gilaka's large shareholding (~77.57 lakh shares) suggests significant promoter/insider alignment, which may be viewed positively by shareholders for continuity. No material impact on stock price expected.